Inflammatory myopathies

Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy

Arthritis Res TherPublished Retrospective observational study

Authors' conclusion

Among patients with IIM, the presence of ILD was linked to higher mortality. Certain autoantibodies, notably anti-ARS and anti-Ro-52 antibodies, were associated with an increased risk of ILD. The greatest risk of ILD was observed in cases of dual positivity for anti-ARS and anti-Ro-52 antibodies.

Study context

Population
Patients who underwent myositis autoantibody testing between July 2018 and January 2021 at one hospital, diagnosed with IIM or IIM-mimics
Participants
604 patients
Exposure
IIM vs IIM-mimics; within IIM, interstitial lung disease (ILD) vs no ILD and myositis antibody categories
  • IIMn = 190
  • IIM-mimicsn = 414reference
Outcome
Occurrence of ILD in IIM, by myositis antibody category
Methodological detailssingle-centre, logistic regression or Firth's logistic regression
  • Single-centre
  • Logistic regression or Firth's logistic regression

Main finding

As reported in the abstract

Risk of ILD by antibody category in IIM
Any myositis-specific antibody (MSA): increased risk of ILD
six-fold
Dual positivity MSA + anti-Ro-52: risk of ILD
twenty-fold
Anti-ARS: increased risk of ILD
14-fold
Dual positivity anti-ARS + anti-Ro-52: risk of ILD
38-fold
Anti-Ro-52 alone: increased risk of ILD
eight-fold

Observational data: associations, not effects.

Further findings

IIM vs IIM-mimics

IIM: higher incidence of ILD, concurrent autoimmune disease, and greater likelihood of various myositis autoantibodies vs IIM-mimics

IIM with vs without ILD

ILD: later age of IIM onset, increased mortality, more frequent anti-ARS antibodies vs without ILD

Original publication

Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy. Arthritis Res Ther. Published 22 August 2024. doi:10.1186/s13075-024-03382-x

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.